Dr. Jun Zhang, MD

Dr. Zhang practices at Houston Methodist Hospital in Houston, Texas, part of Houston Methodist.

Dr. Zhang's NPI, 1184822280, was assigned on July 10, 2007. Dr. Zhang graduated from Hunan Medical University in 1992. Dr. Zhang holds Texas license P1951.

Dr. Zhang's primary practice is Houston Methodist Hospital, at 6565 Fannin, Houston, TX 77030 in Harris County. The practice phone is (713) 790-2221.

Dr. Zhang's primary practice is Houston Methodist Hospital in Houston, Texas, part of Houston Methodist. Dr. Zhang is also affiliated with Houston Methodist West Hospital. The medical group on file is Houston Methodist Specialty Physician Group. Dmand AI also links Dr. Zhang to 3 more hospitals, 2 group practices and clinics, 1 home health agency, 1 skilled nursing facility and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Zhang practices, 9 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Zhang's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Zhang is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Zhang's licenses on file in 2 states: Texas and North Carolina.

Dmand AI lists breast cancer, lung cancer, lymphoma, neutropenia and prostate cancer among the conditions Dr. Zhang treats.

CMS data shows 595 Medicare services from Dr. Zhang across 6 procedure codes in 2024, for 168 Medicare patients. Medicare paid $63,486 for them.

CMS counts 168 Medicare patients who saw Dr. Zhang in 2024. The largest group is 65 to 74, with 78 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 8% are also on Medicaid. Their average risk score is 2.68, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Zhang's median patient age at 74, with 41% women.

In 2024, Dr. Zhang wrote 1,066 Medicare Part D claims for 152 patients. 67% of them were for generic drugs. CMS names the drug for 835 of them, across 28 drugs with 11 or more claims each, at $4,055,090 in total drug cost. In 2023, CMS named 650 claims across 25 drugs.

Dr. Zhang accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Zhang as offering telehealth.

Dmand AI links 21 papers to Dr. Zhang, published from 2012 to 2024. 2023 was the busiest year, with 8. The most frequent topics are Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Carcinoma, Non-Small-Cell Lung. Dr. Zhang has published most often in Urol Oncol. Dr. Zhang's most frequent co-authors are Eric H. Bernicker, MD, Edward Brian Butler, MD and Eleni Efstathiou, MD.

Dmand AI links Dr. Zhang to 14 clinical trials, 5 of them phase 2 studies. 8 are still active or recruiting. Conditions studied include Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung and Lung Neoplasms. National Cancer Institute (NCI) sponsors the most, 3. Open Payments lists research payments to Dr. Zhang that name 4 trials.

CMS Open Payments shows 309 general payments to Dr. Zhang from 45 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 69% of the total. AstraZeneca Pharmaceuticals LP paid the most, $12,328. It also lists 13 research payments totaling $1,810 from 2023 to 2025, naming 4 clinical trials.

Dr. Zhang graduated from Hunan Medical University in 1992.

Dr. Zhang is in network with 22 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 13. Check the plan with the practice before a visit.